---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-23-000027"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T10:39:00.277526+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lisata Q1 net loss $6.2M; cash $61.1M; LSTA1 advances but LSTA201 disappoints

## Summary
- Q1 net loss $6.2M vs $4.2M YoY; R&D $3.2M, G&A $3.7M.
- Cash, equivalents & marketable securities $61.1M as of Mar 31; plus $2.2M non-dilutive NJ tax credit received Q2.
- LSTA1: first patient dosed in iLSTA trial for pancreatic cancer; basket trial in solid tumors planned before end of Q2 2023.
- LSTA201 for diabetic kidney disease showed safety but no consistent kidney function improvement; development only with partner.
- HONEDRA (LSTA12) for critical limb ischemia in Japan: pre-consultation with PMDA; seeking partner.

## SEC filing metadata
- accession: 0000320017-23-000027
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001723000027/0000320017-23-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001723000027/clbs-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-23-000027
- JSON: https://secwatch.observer/filing/0000320017-23-000027.json
- Plain text: https://secwatch.observer/filing/0000320017-23-000027.txt

## Key facts
- Earnings Releases
  LISATA THERAPEUTICS, INC. reported financial results for the three months ended March 31, 2023.
  - Period: the three months ended March 31, 2023
  - Result: reported results
  source text: Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/320017/000032001723000027/0000320017-23-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.